A patient with relapsed, refractory lupus nephritis achieved durable clinical and renal remission following treatment with allogeneic CD19-targeted CAR-NK cells in an open-label clinical trial. The report positions the therapy as a potentially durable alternative for a disease area that often requires repeated immunosuppression and carries substantial renal morbidity. The case adds to the growing body of evidence exploring CAR-cell platforms beyond autologous CAR-T, including off-the-shelf allogeneic approaches that aim to shorten manufacturing lead times and broaden access. For clinical developers, the key next steps are to expand beyond single-case signals and validate durability, safety, and renal response kinetics. The provided text does not specify dose, conditioning, or biomarker endpoints, so the central value remains the durable remission outcome that can inform trial design for subsequent cohorts and dose-finding strategies.